Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evaluation of Biomarkers for Sacituzumab Govitecan in Metastatic Non-Small Cell Lung Cancer: Insights From the EVOKE-01 Study.

Cancer research communications - 1 Aug 2026

Felip Enriqueta, Kuo Peiwen, Garrido Pilar, Chouaid Christos, Mountzios Giannis, Tiseo Marcello, Daniel Davey B, Zavodovskaya Marianna, Tang Shan, Su-Feher Linda, Patel Riddhi, Park Joseph K, Jürgensmeier Juliane M, Summers Yvonne

Abstract excerpt

PURPOSE: This exploratory analysis assessed predictive biomarkers for sacituzumab govitecan (SG) in the open-label, phase III EVOKE-01 study of SG versus docetaxel in non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: Trophoblast cell-surface antigen (Trop) 2 membrane protein expression was analyzed using immunohistochemistry in the Trop-2 biomarker-evaluable population (BEP). Circulating tumor DNA (ctDNA)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to AMP-Activated Protein Kinase Kinases
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antigens, Neoplasm

Share to Camptothecin

Share to Cell Adhesion Molecules

Share to Docetaxel

Share to Immunoconjugates

Share to Kelch-Like ECH-Associated Protein 1

Source

Open in PubMed Open full text

Identifiers

PMID: 42447505
DOI: 10.1158/2767-9764.CRC-26-0070
PMCID: PMC13446097

Genes

TP53
KEAP1
KRAS
STK11

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evaluation of Biomarkers for Sacituzumab Govitecan in Metastatic Non-Small Cell Lung Cancer: Insights From the EVOKE-01 Study.PMID 42447505Read ↗

Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials.Semantic proximity Read ↗

Trop-2 expression in non–small cell lung cancerSemantic proximity Read ↗

Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non-Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy.Semantic proximity Read ↗

Sacituzumab Tirumotecan in EGFR-TKI-Resistant, EGFR-Mutated Advanced NSCLC.Semantic proximity Read ↗

ADC Target Profiling in NSCLC: Generalizable AI Separates TROP-2 and cMET Phenotypes.Semantic proximity Read ↗

EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer.Semantic proximity Read ↗

Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study.Semantic proximity Read ↗

Noninvasive molecular imaging using anti-Trop-2 aptamer for targeted therapy of small cell lung cancerSemantic proximity Read ↗

Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast CancerSemantic proximity Read ↗

Germline Genetic Modulation of Systemic TROP2 Abundance: A Human Genetics–Guided Framework for Stratification of TROP2-Directed Antibody–Drug ConjugatesSemantic proximity Read ↗

A signal-seeking phase 2 study of Trastuzumab emtansine in tumours harbouring HER2 amplification or mutationSemantic proximity Read ↗

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.